OBJECTIVEdTo determine which measuresdimpaired fasting glucose (IFG), elevated HbA 1c , or bothdbest predict incident diabetes in older adults.
I mpaired fasting glucose (IFG) (100-125 mg/dL) has been traditionally used for identifying persons at high risk for the subsequent development of diabetes in the U.S. Recent guidelines have additionally endorsed the use of HbA 1c 5.7-6.4% to identify those at risk (1) . However, multiple studies, including one conducted among older persons (2) , suggest that HbA 1c may identify different individuals at risk for diabetes than traditional glucose measures (3) (4) (5) (6) . Although several recent investigations confirm that HbA 1c is strongly predictive of future diabetes in predominantly middle-aged populations (7) (8) (9) (10) , less is known about how well HbA 1c identifies older persons at risk for diabetes.
Despite the high prevalence of type 2 diabetes in the elderly (10.9 million Americans in 2010) and the high incidence (390,000 new cases in 2010) of late-onset type 2 diabetes (.65 years) (11, 12) , there are few specific studies on prediction of diabetes in this group. One such study, based on an earlier Health, Aging, and Body Composition (Health ABC) analysis, developed a prediction rule for diabetes development, which included several factors: advanced age, female sex, elevated fasting plasma glucose (FPG), and triglyceride levels (13) . However, HbA 1c was not examined as a potential predictor. In the Cardiovascular Health Study of men and women $65 years of age, BMI, waist-to-hip ratio, and weight gain were associated with a higher risk of diabetes, but the impact of glycemic measures on diabetes was not specifically examined (14) . An Italian study of older adults (age 65-84 years) found that the combination of abnormal FPG (defined using World Health Organization [WHO] criteria: 110 to ,126 mg/dL), increased waist circumference, and HbA 1c $7.0% increased the probability of incident diabetes roughly 14-fold (15) . However, neither a direct comparison of current prediabetes categories (based upon FPG and HbA 1c ) for prediction of diabetes nor an analysis of the utility of combined testing has previously been conducted in this population.
We therefore evaluated the odds for diabetes based upon baseline IFG and elevated HbA 1c among the participants of the longitudinal Health ABC study. We directly compared FPG-and HbA 1c -based criteria for predicting the eventual development of diabetes, and we evaluated the utility of combined testing for identifying older persons who develop diabetes. Since HbA 1c values are consistently higher in blacks compared with whites (3, 16) , we additionally explored race differences in diabetes prediction.
RESEARCH DESIGN AND
METHODSdParticipants were from the Health ABC study, an ongoing longitudinal study that investigates changes in body composition as a common pathway by which multiple diseases contribute to disability. Participants (n = 3,075; 48.4% male and 41.6% black, aged 70-79 years) were recruited in 1997-1998 from Pittsburgh, Pennsylvania, and Memphis, Tennessee, using procedures previously described (17) . A telephone interview determined eligibility using the following inclusion criteria: no difficulty performing activities of daily living, walking one-quarter of a mile or climbing 10 steps without resting; no reported need of assistive devices (e.g., cane, walker); no active treatment for cancer in the prior 3 years; no life-threatening illness; and no plans to leave the area for 3 years. Participants provided informed consent before examinations, and the study was approved by institutional review boards at the University of Pittsburgh and the University of Tennessee Health Science Center.
A National Glycohemoglobin Standardization Program (NGSP)-certified HbA 1c assay using modern chromatographic techniques was performed for the first time at the 2000-2001 followup (year 4), which served as the baseline visit for this analysis. Of the 3,075 participants in the Health ABC study, we excluded 187 who did not survive to baseline, 634 who had diagnosed diabetes (based on annual self-report from 1997 to baseline, the use of antihyperglycemic medication from 1997 to 1 year prior to baseline [medication use was not available at baseline], or HbA 1c $6.5% or FPG $126 mg/dL at our baseline visit), and 464 participants who had missing HbA 1c or FPG values at baseline. Finally, we also excluded participants without adequate follow-up after baseline, including 59 survivors who did not develop diabetes, but were missing at the final examination at year 7, and 41 participants who did not develop diabetes, died during follow-up, and missed the clinical visit within 1 year of death (because we could not determine whether they developed diabetes). Our 
Other measures
In addition to age, race, sex, and site (Pittsburgh vs. Memphis), several known risk factors for diabetes were assessed at baseline, including BMI, systolic blood pressure (average of two sitting systolic blood pressure measurements), and selfreported physical activity (weekly walking time). Smoking status was based on self-report and was available 1 year prior to baseline.
Statistical analysis
Multivariable logistic regression analyses were performed to estimate the odds ratios of incident diabetes (from baseline to year 7). The multivariable models were adjusted for age, sex, race, site, systolic blood pressure, BMI, smoking, and weekly walking time (none, ,150 min/ week, or $150 min/week).
To compare the odds of diabetes associated with each prediabetes category, we compared two models: first, IFG was compared with normal FPG (irrespective of HbA 1c ), and second, elevated HbA 1c was compared with normal HbA 1c (irrespective of FPG). Discriminatory ability of each model was assessed using a C statistic with 95% CIs. Model fit was assessed with residual analysis and goodness-of-fit statistics.
To examine the odds of diabetes associated with the combination of the two tests, FPG and HbA 1c , we developed a model with three dummy-coded variables: IFG only, elevated HbA 1c only, and both IFG and elevated HbA 1c (individuals who had neither IFG nor elevated HbA 1c were the reference group), and we calculated odds ratios for these categories. Interaction terms crossing race and sex with the three dummy-coded predictor variables were added to the multivariable logistic regression model to assess race and sex as potential effect modifiers. Odds ratios for the different levels of the effect modifying variable were reported separately for race and sex.
To evaluate the utility of obtaining both tests (HbA 1c and FPG) for predicting diabetes, we compared the fully adjusted model containing IFG with a model that additionally contained elevated HbA 1c . The accuracy of each logistic regression model was assessed by examining both discrimination and calibration. Discrimination is the ability of the model to correctly distinguish those who develop the outcome (diabetes) from those who do not. This was calculated with a C statistic, which estimates the area under a receiver operating characteristic curve (AUC). The difference in the AUC between the two models was compared with the DeLong method (19) . Because the C statistic is a rank-based statistic, it is very difficult for a new marker (in our case, elevated HbA 1c )
to significantly change the value of AUC (20) . Accordingly, two additional measures were useddIntegrated Discrimination Improvement (IDI) and Net Reclassification Improvement (NRI)dto provide additional information beyond AUC (21) . IDI measures the incremental increase in the predicted probabilities for the subset experiencing an event (diabetes) and the incremental decrease for the subset not experiencing an event. The absolute IDI depends on the event rate observed and therefore may be small if events are rare, whereas relative IDI is a percentage. NRI evaluates the net number of individuals reclassified correctly as high versus low risk for diabetes using the model with elevated HbA 1c compared with the model without elevated HbA 1c . This is done by calculating how many individuals who developed diabetes increased in risk category and how many individuals who did not develop diabetes decreased in risk category. Finally, calibration was measured using the HosmerLemeshow x 2 test. Sensitivity analyses. Additional analyses were performed with alternate definitions of the outcome: the first analysis was based on diabetes diagnosed by self-report only (available annually); the second was based on self-report or use of medications only (i.e., without the aid of diagnostic tests performed in the course of the study); the third was based on self-report, use of medications, FPG ($126 mg/dL), or HbA 1c ($6.5%); and the fourth was based on self-report, use of medications, or FPG ($126 mg/dL). To address the timing of diabetes diagnosis, loss to follow-up, and death as a competing variable, we additionally analyzed the data using Cox proportional hazards regression and a Fine and Gray subdistribution hazards model (22) using the primary outcome of diabetes based on self-report, medication use, or HbA 1c $6.5%. In time-to-event models, we used the date of the clinic visit at which diabetes diagnosis was reported or laboratories were performed, and we censored participants at the time of death or at the last clinic visit when they contributed information about diabetes diagnosis.
An additional sensitivity analysis using the WHO definition of IFG, i.e., FPG 110-125 mg/dL, was also performed. When this definition is used, it is specified in the text; when unspecified, IFG refers to the American Diabetes Association (ADA) definition.
All analyses were performed using SAS statistical software (version 9.3, SAS Institute, Cary, NC). P values ,0.05 for two-sided tests are interpreted to indicate statistical significance.
RESULTSdAmong the 1,690 participants during the baseline visit, the mean (SD) FPG was 92.8 mg/dL (9.5), and the median was 92.0 mg/dL (interquartile range 86-98). Respective values for HbA 1c were 5.3% (0.4) and 5.3% (5.1-5.6). The baseline characteristics of study participants are presented in Table 1 Adding HbA 1c to FPG testing The Spearman correlation coefficient between elevated HbA 1c and IFG was 0.31 (P , 0.001), allowing both variables to be included in the same model. Only participants with nonmissing values for all covariates were included in this analysis, resulting in a sample of 1,623, with 172 participants who developed diabetes during follow-up.
The AUC for the fully adjusted model with IFG was 0.76, and the AUC for the model additionally containing elevated HbA 1c was 0.83 (AUC difference 0.07, P value for AUC difference ,0.001). The IDI for evaluation of the added predictive ability of the model with elevated HbA 1c was 0.10 (95% CI 0.08-0.12) with the relative IDI of 101.5% (P value ,0.001). The NRI analysis with a prespecified risk category (,20 vs. $ 20% predicted risk for diabetes) resulted in 13.0% net reclassification improvement (95% CI 4.4-21.7%, P = 0.004) ( Table 3 ). Net reclassification of 11.0% occurred in those with diabetes and 2.0% in those without diabetes. The Hosmer-Lemeshow x 2 test showed P values that were not significant for both models, suggesting that the model fit was acceptable.
Sex and race differences Diabetes developed in 83 (10.7%) of the men and 100 (11.0%) of the women (P = 0.83) and 102 (8.9%) of white and 81 (15.1%) of black participants (P , 0.001). The P values for interaction terms for sex and each of the three dummycoded variables (IFG only, elevated HbA 1c only, and both) were 0.084, 0.016, and 0.002, respectively. Fully adjusted odds ratios for the development of diabetes in men were 8.6 (95% CI 3.4-21.9), 24.2 (9.5-61.8), and 51.1 (21.2-123.2) for IFG only, elevated HbA 1c only, and both IFG and elevated HbA 1c ; in women, the corresponding odds ratios were 1.5 (0.5-4.6), 4.6 (2.4-8.7), and 20.4 (10.9-38.0), respectively.
The interaction terms for race and each of the three dummy-coded variables were not statistically significant. Fully adjusted odds ratios for the development of diabetes in white participants were 3.2 (95% CI 1.5-6.6), 10. by approximately 6-and 11-fold, respectively, compared with normal glycemic parameters. However, when FPG and HbA 1c results are considered together, the odds for diabetes in individuals with both abnormalities were substantially higher (~26-fold). Indeed, the ability to predict whether an older individual will develop diabetes was improved when the results of FPG and HbA 1c were considered together.
Several studies predominantly conducted in the middle-aged populations suggest that HbA 1c is strongly predictive of future diabetes (7) (8) (9) (10) . A recent systematic review involving a total of 44,203 individuals (mean age 53.4 years) showed that the 5-year incidence of diabetes ranged between 25 and 50% for baseline HbA 1c $6% and between 9 and 25% for baseline HbA 1c 5.5-6% across 16 studies (7) . In addition, a recent examination of the value of HbA 1c in the Atherosclerosis Risk in Communities study (mean age 56.7 years) supports its strong association with subsequent diabetes, cardiovascular events, and mortality (23) . One Japanese longitudinal study evaluated the value of HbA 1c in predicting diabetes and compared this directly with FPG (24). Among 6,241 adults without diabetes (mean age 49.9 years) and after a mean follow-up of 4.7 years, the adjusted risk for incident diabetes was increased similarly 6-fold for those with IFG alone and for those with elevated HbA 1c alone, but the risk was substantially higher (nearly 32-fold) for those identified by both IFG and elevated HbA 1c compared with normoglycemic individuals. However, these data are based on analysis of an ethnically homogeneous, predominantly male (75%), and younger cohort, which raises questions with regard to generalizability to older U.S.-based populations.
Few data on the actual incidence of new-onset diabetes in elderly individuals exist in the prior literature. In our study of older adults, 10.8% of participants developed diabetes over 7 years (roughly approximating an annual incidence of ;1.5% per year), which is similar to the annual incidence of diabetes among persons $65 years old in the U.S. (1.5% in 2011, according to the Centers for Disease Control estimates [25] ). The effect of elevated HbA 1c and IFG on the odds of diabetes was comparable in our study with the effect observed in younger populations, although elevated HbA 1c appeared to be a stronger predictor in our study. Proportions of Health ABC participants who developed diabetes over 7 years were 10.6, 21.3, 47.9, and 3.4% in those with IFG alone, elevated HbA 1c alone, both IFG and elevated HbA 1c , and normal parameters at baseline, respectively (compared with the incidence of diabetes over 5 years of 8.5, 7.3, 37.6, and 1.1%, respectively, in the Japanese study) (mean age of 49.9 years [24] ).
The ADA guidelines recommend the use of either test, HbA 1c or FPG, to identify individuals at risk for diabetes (1) . Another option is to measure both tests, either simultaneously or in sequence, but this strategy is more costly (26) . Several investigators have specifically evaluated whether obtaining two tests is better than either one alone in predominantly younger populations. In studies conducted in Japan and China, the ability to predict diabetes with both FPG and HbA 1c was significantly better than with either one alone (27) (28) (29) . In a U.S. study, the incidence of diabetes was substantially increased in those with elevated FPG and HbA 1c compared with those with only one elevated test, but more detailed analyses of combined testing were not performed (8) .
In the Health ABC study, over 7 years, diabetes developed in roughly one of four participants with IFG and one of three participants with elevated HbA 1c dwhen only one of these tests was considered. When both tests were considered together, the probability of diabetes was only 1-2 in 10 for participants with one elevated value (HbA 1c or FPG) and close to 1 in 2 for those with both elevated values. Interestingly, when the WHO definition of IFG was applied (FPG 110 to ,126 mg/dL), participants with this type of IFG had a similar 1 in 2 probability of developing diabetes over time.
In our study, we also compared several measures of discrimination and calibration for models with and without elevated HbA 1c .The AUC, which reflects the ability to distinguish participants who develop diabetes from those who do not, improved significantly when elevated HbA 1c was added to the model already was added to the model, which is a statistically significant difference (P = 0.004). These data suggest that dual screening may improve identification of older participants with the highest odds of developing diabetes when the current definitions of prediabetes endorsed by the ADA are used. One could also argue for a stepwise approach, in which FPG is obtained first. If FPG is elevated by the WHO criterion (110 to ,126 mg/dL), then the risk of diabetes is substantial (48% over 7 years according to our study), and further testing may not be necessary. If, on the other hand, FPG is normal by the ADA criterion (,100 mg/ dL), diabetes risk is quite low at 6% over the next 7 years and, again, additional tests may not be required. When FPG is mildly elevated (i.e., 100-110 mg/dL), measuring HbA 1c may indeed help inform the patient and their care provider of subsequent diabetes risk. Although we did not evaluate the cost-effectiveness of dual testing strategies, our data do provide insight into interpretation of results of both HbA 1c and FPGdwhich are actually often available together in clinical practice.
It is worth noting that many prior studies on prediction of diabetes included only Caucasian subjects (9, 10) or were confined to a single Asian group (24) . It is now well recognized that the use of HbA 1c may differ depending on race, with consistently higher HbA 1c values obtained in black patients (3,16). These differences may reflect higher underlying glucose levels (30) or differences in the duration of hemoglobin exposure to glucose (31) . In our biracial study, black individuals had a higher incidence of diabetes over time than white participants. The interaction between race, baseline glycemic status, and development of diabetes was not significant, suggesting that the overall results of our study can be applied to the black participant subgroup. We did find a significant interaction by sex: the odds ratio for diabetes associated with elevated HbA 1c or IFG was lower among women compared with men. Prior studies have not reported sex differences in prediction of diabetes based upon glycemic measures (8, 32) , and our results will need to be confirmed in future studies.
Our study should be considered in view of several limitations. Data on FPG and HbA 1c were not available at each annual follow-up, and therefore, logistic regression analyses were performed. Odds ratio can overestimate the risk ratio when the outcome of interest is common (.10%) (indeed, the 26.2-fold higher odds of diabetes in those with both elevated HbA 1c and IFG corresponds to a 14.1-fold higher risk ratio using the method of Zhang and Yu [33] ). Our sensitivity analyses, which accounted for time-to-event, yielded qualitatively similar results. We defined the diagnosis of diabetes based on HbA 1c values, selfreport, or medication use and did not apply a single FPG as a criterion. However, the results did not differ substantially when FPG was also considered in the outcome definition in a secondary analysis; however, in that analysis, IFG and elevated HbA 1c each increased the likelihood of diabetes similarly. Finally, we evaluated the impact of elevated HbA 1c and FPG on diabetes diagnosis but not on other outcomes that are important to patients. Effective interventions are available for adults diagnosed with prediabetes to reduce the risk of subsequent diabetes (based on glycemic measures) (34), but it is worth noting that there are no clear data on improvements in clinical outcomes, such as cardiovascular disease or microvascular complications. Future studies will need to evaluate whether screening for diabetes in this age-group with both FPG and HbA 1c leads to better health outcomes and whether this is cost-effective.
In summary, we found that IFG and elevated HbA 1c are associated with increased odds for subsequent diabetes in older adults. Obtaining both tests improves the ability to predict diabetes occurrence. Older adults with both IFG and elevated HbA 1c are at very high risk for diabetes, whereas those with two normal tests are unlikely to develop the disease over the next 7 years. Future studies of new-onset diabetes in older adults are needed to better understand the natural history of this condition and to document the effect of diabetes screening on clinical outcomes in the elderly.
